Cargando…

Varenicline and Nicotine Replacement Use Associated With US Food and Drug Administration Drug Safety Communications

IMPORTANCE: Drug safety communications released by the US Food and Drug Administration (FDA) are often based on limited evidence on safety signals after approval. Varenicline may serve as a relevant case study because it was the target of several FDA communications in 2008 and 2009; ultimately, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desai, Ravi J., Good, Meghan M., San-Juan-Rodriguez, Alvaro, Henriksen, Andrew, Cunningham, Francesca, Hernandez, Inmaculada, Good, Chester B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754175/ https://www.ncbi.nlm.nih.gov/pubmed/31483473 http://dx.doi.org/10.1001/jamanetworkopen.2019.10626

Ejemplares similares

The Food and Drug Administration and varenicline: should risk communication be improved?
por: Davies, Neil M., et al.
Publicado: (2016)

Comparative Effectiveness of Varenicline and Nicotine Replacement Therapy for Smoking Cessation in Older and Younger Smokers: A Prospective Cohort in Taiwan
por: Chang, Po-Yin, et al.
Publicado: (2019)

Adaptive Smoking Cessation Using Precessation Varenicline or Nicotine Patch: A Randomized Clinical Trial
por: Davis, James M., et al.
Publicado: (2023)

Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control
por: Wouda, Jelte A., et al.
Publicado: (2011)

Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials
por: Chang, Ping-Hsun, et al.
Publicado: (2015)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Varenicline Targets the Reinforcing-Enhancing Effect of Nicotine on Its Associated Salient Cue During Nicotine Self-administration in the Rat
por: Garcia-Rivas, Vernon, et al.
Publicado: (2019)

Use of Electronic Nicotine Delivery Systems or Cigarette Smoking After US Food and Drug Administration–Prioritized Enforcement Against Fruit-Flavored Cartridges
por: Kasza, Karin A., et al.
Publicado: (2023)

Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial
por: Tulloch, Heather E., et al.
Publicado: (2016)

Effect of Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Among Smokers Who Drink Heavily: A Randomized Clinical Trial
por: King, Andrea, et al.
Publicado: (2022)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Prospective cohort study of the effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in the “real world”
por: Kotz, Daniel, et al.
Publicado: (2014)

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022)

Prescription Drug Samples: Making Decisions with Imperfect Data
por: Whittle, Jeff, et al.
Publicado: (2008)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
por: Sachs, Rachel E., et al.
Publicado: (2021)

Glycemic Control Was Unchanged in Veterans Health Administration Patients Converted from Glyburide to Glipizide
por: Aspinall, Sherrie L., et al.
Publicado: (2012)

Using cost-effectiveness analysis to support policy change: varenicline and nicotine replacement therapy for smoking cessation in Jordan
por: Madae’en, Saba, et al.
Publicado: (2020)

Varenicline decreases alcohol consumption in heavy-drinking smokers
por: Mitchell, Jennifer M., et al.
Publicado: (2012)

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
por: Skydel, Joshua J., et al.
Publicado: (2022)

Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition
por: San-Juan-Rodriguez, Alvaro, et al.
Publicado: (2019)

An Evaluation of US Food and Drug Administration’s Program to Register HIV Drugs for Use in Resource-Constrained Settings
por: Chahal, Harinder Singh, et al.
Publicado: (2019)

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018
por: Omae, Kenji, et al.
Publicado: (2022)

Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021
por: Daval, C. Joseph Ross, et al.
Publicado: (2023)

Long-term effectiveness and safety of varenicline and nicotine replacement therapy in people with neurodevelopmental disorders: A prospective cohort study
por: Itani, Taha, et al.
Publicado: (2019)

Varenicline for Smoking Cessation: Nausea Severity and Variation in Nicotinic Receptor Genes
por: Swan, Gary E., et al.
Publicado: (2011)

Combination of varenicline and nicotine patch for smoking cessation: A case report
por: Young, Kelly M., et al.
Publicado: (2019)

Evaluation of the nicotine metabolite ratio in smoking patients treated with varenicline and bupropion
por: Tomaz, Paulo Roberto Xavier, et al.
Publicado: (2022)

Combination of behavioral therapy and varenicline for smoking cessation: Time to beat nicotine
por: Agarwal, Avnica, et al.
Publicado: (2022)

Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021
por: Monge, Andrea N., et al.
Publicado: (2022)

Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera, et al.
Publicado: (2021)

Time From Authorization by the US Food and Drug Administration to Medicare Coverage for Novel Technologies
por: Sexton, Zachary A., et al.
Publicado: (2023)

Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial
por: Hajek, Peter, et al.
Publicado: (2013)

Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users
por: Chanfreau-Coffinier, Catherine, et al.
Publicado: (2019)

US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials: A Systematic Review and Meta-analysis
por: Razavi, Marianne, et al.
Publicado: (2019)

Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia
por: Rubino, Annalisa, et al.
Publicado: (2020)

Contents of US Food and Drug Administration Refuse-to-File Letters for New Drug Applications and Efficacy Supplements and Their Public Disclosure by Applicants
por: Chahal, Harinder Singh, et al.
Publicado: (2021)

Varenicline Combined With Oral Nicotine Replacement Therapy and Smartphone-Based Medication Reminders for Smoking Cessation: Feasibility Randomized Controlled Trial
por: Sifat, Munjireen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qf3msa5a8d41r4ta8rc6m5mpl0